公开(公告)号：US20220340527A1

公开(公告)日：2022-10-27

申请号：US17754118

申请日：2020-09-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yuya OGURO ,  Makoto KAMATA ,  Shuhei IKEDA ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO ,  Shigemitsu MATSUMOTO ,  Hirotaka KAMITANI ,  Takaharu HIRAYAMA ,  Toshio TANAKA ,  Hiroshi BANNO ,  Nobuyuki TAKAKURA ,  Jinichi YONEMORI ,  Takuya FUJIMOTO

IPC: C07D211/04 ,  C07D237/08 ,  C07D239/26 ,  C07D405/02

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20190083467A1

公开(公告)日：2019-03-21

申请号：US16083295

申请日：2017-03-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masaki OGINO ,  Eiji KIMURA ,  Shinkichi SUZUKI ,  Kouji FUJI ,  Tomohiro OHASHI ,  Makoto FUSHIMI ,  Kei MASUDA ,  Tatsuki KOIKE ,  Takeshi WAKABAYASHI ,  Jinichi YONEMORI ,  Masami YAMADA

IPC: A61K31/4192 ,  A61K31/4155 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/28

Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.

公开(公告)号：US20230134307A1

公开(公告)日：2023-05-04

申请号：US18087302

申请日：2022-12-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Makoto KAMATA ,  Yuya OGURO ,  Jumpei AIDA ,  Taisuke TAWARAISHI ,  Takeshi WAKABAYASHI ,  Norio OYABU ,  Atsuko OCHIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO ,  Masataka MURAKAMI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Takafumi YUKAWA

IPC: C07D207/263 ,  A61P25/18 ,  C07D401/06

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

公开(公告)号：US20190300536A1

公开(公告)日：2019-10-03

申请号：US16366710

申请日：2019-03-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya OGURO ,  Shigemitsu MATSUMOTO ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO ,  Satoshi MIKAMI ,  Masaki SETO ,  Shinji MORIMOTO ,  Shinji NAKAMURA ,  Sachie TAKASHIMA ,  Masataka MURAKAMI ,  Masaki DAINI ,  Makoto KAMATA ,  Minoru NAKAMURA ,  Yasufumi WADA ,  Hiroyuki KAKEI ,  Kazuaki TAKAMI ,  Taisuke TAWARAISHI ,  Jumpei AIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO

IPC: C07D487/04 ,  C07D471/04 ,  A61K9/20 ,  A61K9/48

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20230150934A1

公开(公告)日：2023-05-18

申请号：US18087233

申请日：2022-12-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Makoto KAMATA ,  Yuya OGURO ,  Jumpei AIDA ,  Taisuke TAWARAISHI ,  Takeshi WAKABAYASHI ,  Norio OYABU ,  Atsuko OCHIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO ,  Masataka MURAKAMI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Takafumi YUKAWA

IPC: C07D207/263 ,  A61P25/18 ,  C07D401/06

CPC classification number: C07D207/263 ,  A61P25/18 ,  C07D401/06

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

公开(公告)号：US20230002318A1

公开(公告)日：2023-01-05

申请号：US17755907

申请日：2020-11-12

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Makoto KAMATA ,  Yuya OGURO ,  Jumpei AIDA ,  Taisuke TAWARAISHI ,  Takeshi WAKABAYASHI ,  Norio OYABU ,  Atsuko OCHIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO ,  Masataka MURAKAMI ,  Minoru NAKAMURA ,  Fumie YAMAGUCHI ,  Takafumi YUKAWA

IPC: C07D207/263 ,  C07D401/06 ,  A61P25/18

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

公开(公告)号：US20220388995A1

公开(公告)日：2022-12-08

申请号：US17550173

申请日：2021-12-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji KIMURA ,  Masaki OGINO ,  Yasuhisa KOHARA ,  Tomoko OHASHI ,  Tomohiro KAKU ,  Yuya OGURO ,  Shigemitsu MATSUMOTO ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO

IPC: C07D409/12 ,  A61P25/28 ,  A61P25/24 ,  A61P25/06 ,  A61K9/20 ,  A61K9/48 ,  C07D231/56 ,  C07D235/06 ,  C07D249/18 ,  C07D401/12

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20210332053A1

公开(公告)日：2021-10-28

申请号：US17201878

申请日：2021-03-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya OGURO ,  Shigemitsu MATSUMOTO ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO ,  Satoshi MIKAMI ,  Masaki SETO ,  Shinji MORIMOTO ,  Shinji NAKAMURA ,  Sachie TAKASHIMA ,  Masataka MURAKAMI ,  Masaki DAINI ,  Makoto KAMATA ,  Minoru NAKAMURA ,  Yasufumi WADA ,  Hiroyuki KAKEI ,  Kazuaki TAKAMI ,  Taisuke TAWARAISHI ,  Jumpei AIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20210139491A1

公开(公告)日：2021-05-13

申请号：US16622632

申请日：2018-06-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kazuaki TAKAMI ,  Masaki SETO ,  Shinobu SASAKI ,  Haruhi ANDO ,  Masaki OGINO ,  Tomoko OHASHI ,  Toshihiro IMAEDA ,  Ikuo FUJIMORI ,  Yasuhiro TSUKIMI ,  Masami YAMADA ,  Kenichiro SHIMOKAWA ,  Takeshi WAKABAYASHI ,  Masataka MURAKAMI ,  Makoto FUSHIMI ,  Tomohiro OKAWA ,  Jinichi YONEMORI ,  Tomohiro OHASHI ,  Hideo SUZUKI ,  Hironobu MAEZAKI ,  Ayumu SATO ,  Yasutomi ASANO ,  Steve SWANN

IPC: C07D491/048 ,  A61K31/4355 ,  A61P1/10

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20200231579A1

公开(公告)日：2020-07-23

申请号：US16634402

申请日：2018-07-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji KIMURA ,  Masaki OGINO ,  Yasuhisa KOHARA ,  Tomoko OHASHI ,  Tomohiro KAKU ,  Yuya OGURO ,  Shigemitsu MATSUMOTO ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO

IPC: C07D409/12 ,  C07D231/56 ,  C07D235/06 ,  C07D401/12 ,  C07D249/18 ,  A61K9/48 ,  A61K9/20 ,  A61P25/06 ,  A61P25/24 ,  A61P25/28

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.